How Death Becomes Life
13 Apr, 2022

You must’ve heard of people being born with genetic defects, like skin conditions and structural abnormalities, but have you ever heard of people who do not stop bleeding?

This bleeding disorder is called Hemophilia. In India, more than 1,36,000 people are diagnosed with this rare genetic bleeding disorder.

War and road accidents are not the only causes of hemorrhage. Surgical procedures are often the cause of blood loss. Accidents happen on a surgery table as well. Hemorrhages are a common occurrence during surgery. Unfortunately, statistics describing the problem of controlling bleeding and using a hemostat are sparse.

Let us first understand what hemophilia is.

When a person bleeds from a small cut, the blood will stop within the next 5 mins. But in hemophilic patients, due to the lack of blood-clotting protein, the bleeding is not controlled, and the person may even die due to blood loss. These people may have different kinds of bleeding, like bleeding gums, prolonged bleeding from dental procedures, or heavy menstrual bleeding depending on the degree of deficiency.

Further, there are two types of hemophilia.

  • Hemophilia A (low levels of factor Ⅷa)
  • Hemophilia B (low levels of factor Ⅸa)

This rare genetic bleeding disorder is diagnosed by doctors when the baby is a year old when they inspect severe bruising or have prolonged bleeding.

This bleeding disorder might be rare, but did you know…….Queen Victoria of England was believed to have carried and passed on hemophilia B?

This is why hemophilia is sometimes called “the royal disease .” It affected the royal families of Russia, England, Spain, and Germany in the 19th and 20th centuries.

Are there any acquired causes of hemophilia?

While this condition is majorly genetic, there might be some cases where it is non-inherited. This means that change or mutation in Factors Ⅷa or Ⅸa can also cause hemophilia.

Having an idea of how rare and deadly this bleeding disorder is, can we treat it?

The treatment method and the frequency are determined, but the type, and severity of the bleeding disorder. As we know, the hemophilic patient’s bleeding cannot stop on its own due to a lack of blood-clotting proteins. In this case, they may suffer from significant blood loss. As bandages are not enough, there arises a need for a revolutionary hemostatic agent. Brought to India by Swasth Kare, SeraSeal™ is the World’s first and Only primary hemostatic agent that stops bleedings in seconds.

The active agents in SeraSeal™ are agar, Factors IIa, VIIa, IXa, and Xa, which are effective in both Hemophilia A and Hemophilia B patients and all other forms of coagulopathy. Agar in SeraSeal™ adds another layer of hemostasis to a bleeding wound by binding to the patient’s platelets to form a platelet plug to seal the wound. Agar is effective in patients on platelet inhibitor therapy by binding to the ions of platelet phospholipids and cations from amine groups in the fibrinogen/fibrin monomers and tissue proteins to form a gelatin barrier over the wound. Additionally, Phase 1 clinical trial had 24 heparin patients in both SeraSeal™ and cauterization groups, where SeraSeal™ achieved a hemodialysis mean collective time of 0.72 min compared to a collective mean of 10.00 min in the cauterized group.

How is SeraSeal™ beneficial in treating the two types of hemophilia?

While this condition is majorly genetic, there might be some cases where it is non-inherited. This means that change or mutation in Factors Ⅷa or Ⅸa can also cause hemophilia.

Hemophilia A

The active factor Xa in SeraSeal™ bypasses the patient’s Factor VIIIa deficiency and catalyzes the standard coagulation cascade system at Factor Xa to form a Fibrin clot within seconds.

Hemophilia B

The active factor IXa in SeraSeal™ bypasses the patient’s Factor IXa deficiency and catalyzes Factor VIIa in the intrinsic coagulation cascade system, creating a Fibrin clot within seconds.

SeraSeal™ represents a new generation of medical devices in the form of technology that improves surgical efficiency on hemophilic patients, reduces cost, and dramatically impacts patient outcomes. Both ethically and economically, it is time to usher in this revolutionary hemostatic agent.

To know how SeraSeal™ works, contact us today!

Reference Links:

13 Apr, 2022

Add your comment

Your email address will not be published. Required fields are marked *

Subscribe to the newsletter

Receive latest news and updates